The second birth of the drug Amizon®: the results of international scientific studies confirm the antiviral effect

September 5, 2018
1069
Resume

The article presents modern data on the use of antiviral drugs in influenza and other acute respiratory viral infections, the results of scientific research and development of innovative medicines for the treatment of patients with influenza. Data from large-scale preclinical and clinical studies confirm the high antiviral efficacy of enisamium iodide (Amizon®), an attractive drug profile and the ability to reduce the risk of complications.

A.F. Frolov, O.A. Golubovska, S.O. Kramarev, A.P. Mironenko, V.M. Margitich

Key words: acute respiratory viral infections, influenza, antiviral drugs, enisamium iodide, Amizon®.

Published: 04.09.2018

References:

  • Abe K., Aoki M., Tsuji S. et al. (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol., 16(7): 505–512.
  • Ashton L.V., Callan R.L., Rao S., Landolt G.A. (2010) In vitro susceptibility of canine influenza A (H3N8) virus to nitazoxanide and tizoxanide. Vet. Med. Int. (https://www.hindawi.com/journals/vmi/2010/891010/).
  • Boltz D., Cocking D., Cinatl J. et al. (2017) Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. 5th ISIRV AVG Conference, Shanghai, China, 110 p.
  • Boltz D., Peng X., Muzzio M. et al. (2014) Antiviral activity of enisamium against influenza viruses in differentiated normal human bronchial epithelial cells. 3rd Antivirals Congress, October 12–14, Amsterdam, Netherlands.
  • Cocking D., Cinatl J., Boltz D.A. et al. (2018) Antiviral effect of a derivative of isonicotinic acid enisamium iodide (FAV00A) against influenza virus. Acta Virol., 62(2): 191–195.
  • Colman P.M. (1994) Influenza virus neuraminidase: structure, antibodies, and inhibitors. Protein Sci., 3: 1687–1696.
  • De Witt M., Gamble A., Hanson D. et al. (2017) Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors. Mol. Med., Apr. 5 [Epub. ahead of print].
  • Fiore A.E., Fry A., Shay D. et al.; Centers for Disease Control and Prevention (CDC) (2011) Antiviral agents for the treatment and chemoprophylaxis of influenza — recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep., 60(1): 1–24.
  • Huber V.C. (2014) Influenza vaccines: from whole virus preparations to recombinant protein technology. Expert Rev. Vaccines, 13(1): 31–42.
  • Laurent K., Wat C., Mills T. et al. (2003) Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch. Intern. Med., 163(14): 1667–1672.
  • Mestre-Ferrandiz J., Sussex J., Towse A. (2012) The R&D Cost of A New Medicine. Office of Health Economics, London, 100 p.
  • Rossignol J.F. (2014) Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral. Res., 110: 94–103.
  • WHO (2014) Influenza (Seasonal) (http://www.who.int/mediacentre/factsheets/fs211/en/).
  • WHO (2017a) Model List of Essential Medicines for Children (http://apps.who.int/iris/bitstream/handle/10665/273825/EMLc-6-eng.pdf?ua=1).
  • WHO (2017b) The Selection and Use of Essential Medicines (http://www.who.int/medicines/publications/essentialmeds_committeereports/en/).
  • WHO (2018) New ATC (https://www.whocc.no/atc/lists_of_new_atc_ddds_and_altera/new_atc).
  • Wohner N., Varga G., Szloboda P. et al. (2017) Thalidomide therapy in relapsed diffuse large B-cell lymphoma in elderly patients. Three cases. Orv. Hetil., 158(41): 1642–1648.